Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays

Journal of Pharmaceutical and Biomedical Analysis

Volumn 43, Issue 4, 2007, Pages 1256-1261

  Jaber, Amer ^a   Baker, Matthew ^b  

^a Serono International SA   (Switzerland)

^b Antitope Ltd   (United Kingdom)

Author keywords

Dendritic cell; Immunogenicity; Interferon beta 1a; Multiple sclerosis; New formulation; T cell

Indexed keywords

BENZYL ALCOHOL; BETA1A INTERFERON; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; LYSINE; MANNITOL; METHIONINE; POLOXAMER;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG ANTIGENICITY; DRUG FORMULATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; BIOLOGICAL ASSAY; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; INTERLEUKIN-2; MULTIPLE SCLEROSIS; REFERENCE STANDARDS; T-LYMPHOCYTES; TIME FACTORS;

EID: 33847301389     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2006.10.023     Document Type: Article

References (23)

1. Schellekens H. Neurology 61 (2003) S11-S12
2. Ross C., Clemmesen K.M., Svenson M., Sorensen P.S., Koch-Henriksen N., Skovgaard G.L., and Bendtzen K. Ann. Neurol. 48 (2000) 706-712
3. Durelli L., and Ricci A. Front Biosci. 9 (2004) 2192-2204
4. Schellekens H. Nat. Biotechnol. 22 (2004) 1357-1359
5. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 47 (1996) 889-894
6. The PRISMS (Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 56 (2001) 1628-1636
7. Goodin D.S., Frohman E.M., Garmany Jr. G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., and van den Noort S. Neurology 58 (2002) 169-178
8. Antonelli G., Bagnato F., and Dianzani F. New Microbiol. 28 (2005) 183-192
9. Schlienger K., Craighead N., Lee K.P., Levine B.L., and June C.H. Blood 96 (2000) 3490-3498
10. Hochuli E. J. Interferon Cytokine Res. 17 (1997) S15-S21
11. Ruiz L., Reyes N., Duany L., Franco A., Aroche K., and Hardy Rando E. Int. J. Pharmacol. 264 (2003) 57-72
12. Polman C., Kappos L., White R., Dahlke F., Beckmann K., Pozzilli C., Thompson A., Petkau J., and Miller D. Neurology 60 (2003) 37-43
13. Petkau A.J., White R.A., Ebers G.C., Reder A.T., Sibley W.A., Lublin F.D., and Paty D.W. Mult. Scler. 10 (2004) 126-138
14. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., Mass M.K., Richert J.R., Salazar A.M., Munschauer III F.E., Cookfair D.L., Simon J.H., and Jacobs L.D. Neurology 50 (1998) 1266-1272
15. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. Neurology 56 (2001) 1628-1636
16. Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Neurology 56 (2001) 1496-1504
17. The IFNB Multiple Sclerosis Study Group. Neurology 43 (1993) 655-661
18. European Study Group on Interferon β-1b in Secondary Progressive MS. Lancet 352 (1998) 1491-1497
19. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., and Berger T. Neurology 52 (1999) 1239-1243
20. Rice G.P., Paszner B., Oger J., Lesaux J., Paty D., and Ebers G. Neurology 52 (1999) 1277-1279
21. Pozzilli C., Antonini G., Bagnato F., Mainero C., Tomassini V., Onesti E., Fantozzi R., Galgani S., Pasqualetti P., Millefiorini E., Spadaro M., Dahlke F., and Gasperini C. J. Neurol. 249 (2002) 50-56
22. Kappos L., Traboulsee A., Constantinescu C., Eralinna J.-P., Forrestal F., Jongen P., Pollard J., Sandberg-Wollheim M., Sindic C., Stubinski B., Uitdehaag B., and Li D. Neurology 67 (2006) 944-953
23. Barbosa M.D., Vielmetter J., Chu S., Smith D.D., and Jacinto J. Clin. Immunol. 118 (2006) 42-50